Balchem Corporation Q2 FY2025 earnings call

Management Statement and Operational Highlights

• Market Environment: Healthy demand across end markets. Advantages include 85% of sales manufactured in the same region they are sold, global supply chain not reliant on China, robust U.S. manufacturing, and ability to raise prices to offset costs.
• Segment Performances: Human Nutrition & Health strong due to good-for-you trends; Animal Nutrition & Health benefited from EU antidumping duties on Chinese choline; Specialty Products performing well with higher demand in Performance Gases and Plant Nutrition.
• Scientific Research: Over 20 active clinical studies focused on nutrients; Q2 had six significant publications, including one on dietary choline and Alzheimer's disease, and another on OptiMSM and exercise-induced oxidative stress.
• Capacity Expansion: Announced a $36 million state-of-the-art microencapsulation manufacturing facility in Orange County, NY, expected to more than double capacity.

Segment Performance

• Human Nutrition & Health: Record sales of $161 million, a 8.7% increase year-over-year. Delivered record quarterly earnings from operations of $38 million, up 14.9% year-over-year. Driven by higher sales in Food Ingredients and Solutions and nutrients businesses.
• Animal Nutrition & Health: Quarterly sales of $56 million, a 13.1% increase year-over-year. Earnings from operations were $4 million, up 30.5% year-over-year. Growth due to higher sales in ruminant and monogastric species markets.
• Specialty Products: Record quarterly sales of $37 million, a 6% increase year-over-year. Record earnings from operations of $11 million, up 0.4% year-over-year. Performance driven by higher demand in Performance Gases and Plant Nutrition businesses.

Guidance

• Outlook for the second half of 2025 remains positive.
• Confident in long-term growth despite global trade challenges, leveraging strong market positions and value-added product portfolio.

Risks

• Tariffs: Impact on raw material costs estimated at ~$25 million. Half to be offset by supply chain shifts and alternate suppliers; half to be addressed through pricing adjustments.

Question and Answer

Q: Congratulations on the recent antidumping news. Could you give an update on the macro environment and drivers for growth in A&H?

A: Monogastric demand stable; ruminant and companion animal businesses offer growth opportunities. Ruminant side has innovation like new products, and companion animal business provides growth opportunities.

Q: Talk more about the manufacturing facility investment. How much capacity, timeline, and funding?

A: Purpose-built facility in NY, expected to double capacity, take ~2 years, funded by existing cash and debt. CapEx spending will be within existing range, with production expected late 2027 into 2028.

Q: Status of VitaCholine, Pro-Flo and strategic outlook on human health?

A: VitaCholine and Pro-Flo are being introduced to customers with positive reception. Market trends moving towards health side, continuing science investments while investing in marketing.

Q: Tariffs impact and CureMark update?

A: Tariffs impact ~$25 million, half offset by supply chain moves, half by pricing; CureMark preparing to file BLA with FDA.

Q: Breakdown of A&H growth and stock repurchases?

A: A&H growth: monogastric up 7%, ruminant up 30%; stock repurchases are opportunistic for anti-dilutive purposes, not a shift in strategy.

Q: H&H growth breakdown between nutrients and ingredients?

A: Nutrients business grew 8.8% organically, Food Ingredients and Solutions grew 8.6% organically. K2 product line growing double digits, MSM and Minerals also growing strongly.